Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
Recruiting
Observational Study
Growth Hormone Deficiency
Idiopathic Short Stature
Turner Syndrome
Small for Gestational Age
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 2 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 5,000 (estimated)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
* Children who has official height record at least 6 months prior
Exclusion Criteria:
* Children with Epiphyseal closure
Contacts